Fundraising FoxTVAX Biomedical
Olathe, US · Delaware corporation
Find your way into TVAX Biomedical
Sign up to see every warm intro you have to TVAX Biomedical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TVAX Biomedical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TVAX Biomedical develops TVAX Immunotherapy, a personalized adoptive T cell therapy for cancer patients that combines a vaccination step using a patient's own cancer cells with activated killer T cell treatment. Its lead candidate, TVI-Brain-1, is in a phase 2b clinical trial for glioblastoma (brain cancer) and has received FDA Fast Track Designation.
Founders & leadership
TA
Tammie A. WahausExecutive
LL
Lowell L. TilzerExecutive
CE
Catherine E. LucaseyExecutive
Board
BS
Barry S. SkikneBoard director
CB
Charles BurtonBoard director
WG
Wesley GriffittBoard director
Reported raises · per SEC filings
Form D private placements$325.1K disclosed across 1 round · 2016
▶$325.1KraisedJul 2016 · 14 investors · BiotechnologyRule 506(b)
▶$325.1KraisedJul 2016 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry S. SkikneDirector
- Charles BurtonDirector
- Tammie A. WahausExecutive Officer
- Lowell L. TilzerExecutive Officer, Director
- Catherine E. LucaseyExecutive Officer, Director
- Wesley GriffittDirector
- Gary W. WoodDirector
- Offering amount
- $500K
- Amount sold
- $325.1K
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 10
DynavaxDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
VaccinexVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
CentivaxCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
CancerVAXCancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
CellVax TherapeuticsCellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
MimiVax, LLCMimiVax is a biopharmaceutical company developing immunotherapies for brain tumors, particularly glioblastoma, by harnessing the immune system to target cancer cells. The company's lead candidate, SurVaxM, is a peptide-based vaccine targeting survivin in cancer cells across multiple indications including glioblastoma, multiple myeloma, and neuroendocrine tumors.
Genvax TechnologiesGenvax Technologies develops mRNA and nanoparticle-based vaccines for livestock, focusing on custom, herd-specific formulations that aim to improve speed and precision compared to conventional vaccine platforms. The company serves animal health and food supply sectors.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
AbivaxAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
ImvaxImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Companies working in the same space as TVAX Biomedical.
Frequently asked questions
- What does TVAX Biomedical do?
- TVAX Biomedical develops TVAX Immunotherapy, a personalized adoptive T cell therapy for cancer patients that combines a vaccination step using a patient's own cancer cells with activated killer T cell treatment. Its lead candidate, TVI-Brain-1, is in a phase 2b clinical trial for glioblastoma (brain cancer) and has received FDA Fast Track Designation.
- Who founded TVAX Biomedical?
- TVAX Biomedical was founded by Gary W. Wood.
- How much funding has TVAX Biomedical raised?
- TVAX Biomedical has disclosed $325.1K raised across 1 round.
- Where is TVAX Biomedical headquartered?
- TVAX Biomedical is headquartered in Olathe, US.